HeartBeam reports Q3 2025 results, missing EPS estimates. The pre-revenue firm focuses on FDA clearance for its cardiac tech, a key milestone expected by year-end.
HeartBeam (NASDAQ: BEAT) has cemented its position as a vanguard in medical technology, earning multiple prestigious accolades that underscore its groundbreaking contributions to portable ECG innovation. Most notably, the company was recently identified as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest's "Total Cardiac Intelligence" report, placing it second worldwide in [...]
HeartBeam Inc. reports Q2 2025 results with a net loss of $5M, beating EPS estimates. FDA clearance for ECG tech expected by year-end amid steady cash burn. Stock shows mixed reaction.
Shares of FedEx Corporation (NYSE: FDX) rose sharply in today’s pre-market trading after the company reported better-than-expected earnings for its third quarter and authorized a new $5 billion
Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ:TIGR) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million.
Heartbeam shares are trading higher by 3.5% to $2.35 Tuesday, pulling back following the session high of $2.70. The company last week said it secured two new patents.
